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Clinical Case Report and Review
ABSTRACT
Merkel cell carcinoma is an aggressive malignancy that frequently recurs/disseminates, but metastases to the genitourinary 
tract are rare. Only eight cases of Merkel cell carcinoma metastatic to the testis are reported. We describe the ninth case 
of this event and provide a review of the literature. A 58-year-old man diagnosed with Merkel cell carcinoma of the wrist, 
presented, 37 months later, a recurrence in the form of a testicular metastasis. The tumor consisted of a monotonous 
proliferation of small, blue, round cells, with immunoexpression of neuroendocrine markers and the typical dot-like 
paranuclear immunostaining for cytokeratin 20, in the absence of immunostaining for cytokeratin 7. The patient is alive 
with no evidence of disease. Clinicians should be aware of the possibility of metastatic dissemination to the testis since 
genital examination/imaging is not part of routine follow-up for these patients, but timely orchiectomy may be curative. 
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INTRODUCTION
Merkel cell carcinoma (MCC) is an uncommon, 
and aggressive cutaneous neuroendocrine neoplasm, 
mostly located in the head and neck region (40-50% of 
the cases) with a high rate of local recurrence or distant 
metastasis (80%) within 2-3 years after diagnosis.1,2
Occult metastatic dissemination is already present 
at diagnosis in 30% of patients, mostly to lymph nodes. 
Distant metastatic sites include the liver, bone, lung, 
brain, adrenal gland, and skin.1 Metastases to the 
genitourinary tract are less common.
To the best of our knowledge, only eight cases 
of Merkel cell carcinoma metastatic to the testis were 
reported in the English literature. Herein, we report 
the ninth case and review the literature.
Case Report
A 58-year-old man was diagnosed with MCC 
of the left wrist and underwent local excision in a 
peripheral center. The tumor was composed of dense 
and diffusely infiltrative blue cells centered in the 
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dermis (Figure 1A), diffusely positive for Synaptophysin 
(Figure 1B), CK20 (in the dot-like pattern) and the Ki67 
index was high (Figure 1C). As the resection margins 
were not free of tumor (Figure 1D), the patient was 
referred to the Oncologic Institute.
At the f irst appointment, he presented a 
remaining ulcerating lesion on the wrist and no 
further complaints. He had a history of hypertension, 
adenoma of the adrenal gland, obesity, hyperuricemia, 
and colonic diverticulosis. The computed tomography 
scan showed a large homolateral axillary mass. 
He underwent wide local excision of the wrist tumor 
and the axillary lymph node dissection. As the 
histopathological examination showed evidence of 
metastatic disease (Figure 2A and 2B), and invasion 
of adipose and muscular tissues, chemotherapy (four 
courses of cisplatin, 150.4mg in 1000mL NaCl 0.9%, 
and etoposide, 188mg in 500mL NaCl 0.9%) and 
radiotherapy (60Gy in 30 fractions to the left wrist and 
60Gy in 30 fractions to the left axilla) were included 
in the patient’s therapeutic regimen.
Thirty-seven months after MCC initial diagnosis, 
the patient complained of recent-onset scrotal edema. 
The physical examination disclosed a solitary, indurated 
nodule within the left testis. The scrotal ultrasound 
revealed a heterogeneous mass. The laboratory 
workup was unremarkable, including normal 
serum alpha-fetoprotein (AFP), human chorionic 
gonadotropin subunit beta (β-HCG), and lactate 
dehydrogenase (LDH). The patient underwent left 
radical orchiectomy. The macroscopic examination 
revealed a 60×49×40mm white to tan, ovoid, solid 
mass, almost completely replacing the testicular 
parenchyma (Figure 3A). Centrally, areas of necrosis 
were depicted. On histological examination, the 
mass corresponded to a highly cellular, monotonous 
Figure 1. Photomicrograph of the skin. A – The lesion had a solid growth pattern (H&E, 100X); B – It was diffusely 
positive for synaptophysin (100X); C – Ki67 index was high (100X); D – The tumor was present in the surgical margin 
(notice tumor cells present at the red-inked margin) (H&E 200X).
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proliferation of small, blue, round cells. On low 
power field examination, the tumor exhibited a solid 
growth pattern, extensively infiltrating throughout 
the seminiferous tubules, being confined to the 
testis (Figure 3B). Lymphovascular invasion was easily 
identified.
On the higher magnification, the tumor cells 
were often arranged in an organoid and trabecular 
fashion, displaying a scant eosinophilic cytoplasm, 
hyperchromatic enlarged nuclei with coarsely 
granular chromatin, visible nucleoli and brisk mitotic 
activity (Figure 4A). The immunohistochemistry 
panel (see Table 1) revealed a diffuse and robust 
immunoexpression of synaptophysin (Figure 4B), 
chromogranin (Figure 4C) and CD56; dot-l ike 
para nuclear immunostaining for cytokerat in 
20 (Figure 4D) and cytokeratins 8/18; and lack 
of immunoexpression for cytokeratin 7, CD45, 
PLAP, OCT 3/4, TTF-1, CDX2 and PS100 (Table 1). 
A diagnosis of metastatic involvement by MCC was 
made.
The patient is currently under surveillance. He is 
alive with no other signs of disease, 47 months after 
the initial diagnosis of MCC.
Figure 2. Photomicrograph of the lymph node showing in A – metastatic infiltration (HE, 200X); B – positive 
reaction for CK 8/18 (40X).
Figure 3. Macroscopic aspect (A) and histological overview (B) of the Merkel cell carcinoma within the testis. A – The 
lesion was solid, tan, with foci of hemorrhage and necrosis, and replaced almost the entire testicular parenchyma, 
sparing the mediastinum testis; B – The lesion was well demarcated and confined to the testicular parenchyma, 
sparing the rete and mediastinum testis. Vascular invasion was easily identifiable (white arrow).
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Figure 4. Photomicrographs of the tumor - Histological and immunohistochemistry studies of the testis’ Merkel 
cell carcinoma. A – The neoplasm had a solid, somewhat organoid growth pattern, and was composed of tumor 
cells with scant eosinophilic cytoplasm, hyperchromatic nuclei with coarsely granular chromatin and visible nucleoli. 
Numerous mitotic figures were evident (H&E,400X); B – Tumor cells disclosed strong and diffuse immunoexpression 
of synaptophysin (400X); C – multifocal and robust reaction to chromogranin (400X); D – strong and diffuse reaction 
to CK20 (400X).
Table 1. Immunohistochemistry methods.
Antibody Clone Vendor Dilution Detection system Automatic platform
Synaptophysin DAK-SYNAP DAKO 1/150 BPRD kit LB III
Chromogranin DAK-A3 DAKO 1/200 BPRD kit LB III
CD56 CD564 LEICA 1/100 BPRD kit LB III
Cytokeratin 20 Ks20.8 LEICA 1/250 BPRD kit LB III
Cytokeratin 7 OV-TL 12/30 LEICA 1/150 BPRD kit LB III
CAM 5.2 5D3 LEICA 1/100 BPRD kit LB III
CD45 2B11 & PD7/26 DAKO 1/300 BPRD kit LB III
PLAP 8A9 DAKO 1/100 BPRD kit LB III
OCT 3/4 C-10 MASTER DIAGNÓSTICA Prediluted BPRD kit LB III
TTF-1 8G7G3/1 CELL MARQUE 1/200 BPRD kit LB III
PS100 Polyclonal DAKO 1/3000 BPRD kit LB III
Ki67 MIB-1 DAKO 1/200 UUDD kit Ventana
BPRD kit: Bond Polymer Refine Detection Kit; LB III: Leica Bond III; UUDD kit: Ultraview Universal DAB Detection Kit.
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DISCUSSION
MCC is an overall rare neoplasm (0.1 to 1.6 per 
100.000 people per year, depending on the region of the 
globe), which is more prevalent in males and the elderly 
(median age at diagnosis of 75-80 years).1 Incidence 
has been rising in the past years (an age-adjusted 
annual increase of 8%, greater than the one observed 
for melanoma), and the mortality rate is high (33%), 
also higher than that of melanoma.2 MCC has been 
linked to exposure to ultraviolet light and also to 
Merkel-cell polyomavirus, which recently has been 
used as rationale for treatment with immunotherapies, 
namely pembrolizumab. The five-year survival rate of 
patients with distant metastases is 25%, what means 
a guarded prognosis. The increase in life expectancy, 
and the substantial increase in the incidence of 
MCC, impose the need for accurate detection of 
such metastatic disease. Therefore, the screening for 
the most common, and the unusual metastatic sites 
should take part in the clinicians’ approach. Indeed, the 
metastases to the genitourinary tract are not among 
the most common sites. Specifically, to date, only eight 
cases of MCC metastatic to the testis were reported 
in the literature (Table 2), our report is the ninth 
case.3-9 Metastasis to the genital tract is accessible for 
curative surgical excision. It may be overlooked since 
the external genitalia is not routinely examined in the 
MCC surveillance. Neither included in the imaging 
workup.4 All reported cases were, indeed, detected in 
the presence of symptomatic enlargement of the testis, 
except in one case in which metastatic dissemination 
was depicted in both testes by somatostatin receptor 
scintigraphy.
The median age at diagnosis of the MCC testicular 
metastases is 60 years (range: 38-73 years), similar to 
our patient (61 years old), but below the median age 
of 75 years described for diagnosis of primary MCC. 
MCC is intimately related to immunosuppression, 
which favors earlier clinical presentation, besides a 
poorer prognosis.10 Our patient was obese, had hepatic 
steatosis and hyperuricemia, features consistent with 
chronic alcohol consumption, which may express a 
sort of immune system deficiency. It has also been 
hypothesized that metastatic dissemination of MCC to 
the testis may reflect the effect of the hematotesticular 
barrier, which prevents accessibility of chemotherapy 
agents, failing to eradicate minimal residual testicular 
disease.3,5
The time from primary tumor diagnosis to clinical 
detection of metastasis within the testis varied between 
2 to 22 months (median 12 months), in consonance 
with the data on recurrences elsewhere, which is the 
first 2-3 years.1,2 Our patient presented the testicular 
metastasis after 37 months of the primary diagnosis, 
constituting the largest time interval reported to date 
in this specific setting.
Four out of the eight reported patients (50%) 
died of the disease. In the present case, considering 
the presence of a large metastatic axillary mass 
with surrounding tissue invasion, a combination of 
both adjuvant chemotherapy and radiotherapy to 
the primary tumor site and axilla was pursued, as 
considered in the guidelines.11 Despite the recurrence 
in the testis (treated by orchiectomy alone), a good 
outcome was achieved (the patient is alive with no 
evidence of disease 47 months after the primary tumor 
diagnosis).
The differential diagnosis of MCC metastatic to the 
testis can be challenging. The Pathologist should have a 
high index of suspicion since some patterns may mimic 
primary testicular tumors.12 The immunohistochemistry 
studies aid to clinch the precise diagnosis. More 
than 95% of testicular masses correspond to germ 
cell tumors, which are heterogeneous and may 
simulate several entities;13 however, most afflict 
young-adult patients. The overall histological pattern, 
elder patients (over 60 years), and negativity for PLAP 
and OCT3/4 discarded this hypothesis. Metastases 
to the testis/paratesticular area are overall rare (with 
the reported incidence varying from 0.06% to 3.6%), 
and most frequently arise from the prostate.12 In our 
case, the known clinical history of a previous MCC 
with metastases to the lymph-nodes was determinant 
and raised suspicion. In the reported cases, most MCC 
metastases to the testis were unilateral (like in our case), 
which should not refrain from considering a metastasis. 
MCC should be differentiated from other entities with 
possible similar histological and cytological features, 
namely small-cell lung cancer (small-cell) lymphomas 
and anaplastic small-cell melanomas. Negativity for 
CD45, TTF-1, and PS100 aid ruling out these entities. 
Expression of neuroendocrine markers (synaptophysin, 
chromogranin, and CD56) and, importantly, the typical 
dot-like pattern of CK20 immunoexpression (in the 
absence of CK7 immunoexpression) further confirm the 
diagnosis. Of note, since very rarely small-cell carcinoma 
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of the lung may show immunoexpression of CK20, and 
also very rarely MCC may be negative for CK20 and 
positive for TTF-1, it is wise to use a panel of antibodies, 
combined with clinical information, instead of relying on 
a single antibody and risk a misdiagnosis.1 Also, when 
lymphoblastic lymphoma is a concern, it is wise to have 
in mind that TdT expression occurs in MCC.14
To conclude, we report the ninth case of metastatic 
dissemination of MCC to the testis. A high level of 
clinical suspicion and accurate histopathological 
assessment, including immunohistochemistry studies, 
are necessary for the precise diagnosis. Clinicians should 
be aware of this unusual pattern of dissemination since 
orchiectomy can be curative.
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